EDIT Editas Medicine, Inc.
Editas Medicine, Inc. (EDIT) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $41.5K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| O'Neill Gilmore Neil | CEO | Sell | 5,124 | $3.04 | $15.6K | 243,189 −2.1% of holding | |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 709 | $3.04 | $2.2K | 61,660 −1.1% of holding | |
| Parison Amy | SVP, Chief Financial Officer | Sell | 453 | $3.04 | $1.4K | 13,839 −3.2% of holding | |
| Parison Amy | SVP, Chief Financial Officer | Sell | 678 | $2.58 | $1.7K | 14,292 −4.5% of holding | |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 4,928 | $2.67 | $13.2K | 62,369 −7.3% of holding | |
| O'Neill Gilmore Neil | CEO | Sell | 15,380 | $2.70 | $41.5K | 248,313 −5.8% of holding | |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 731 | $2.70 | $2.0K | 67,297 −1.1% of holding | |
| Parison Amy | SVP, Chief Financial Officer | Sell | 464 | $2.70 | $1.3K | 14,970 −3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.